# Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

Study · id `cardio:ct-nct01346865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01346865](<https://clinicaltrials.gov/study/NCT01346865>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01346865

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 402 participants.

## Technical summary

Registry record NCT01346865. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 402 participants (enrolled count; ClinicalTrials.gov record NCT01346865, source copy `cardio:ctgov-nct01346865-2015-11-16`, retrieved 2026-10-26)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01346865, source copy `cardio:ctgov-nct01346865-2015-11-16`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01346865, source copy `cardio:ctgov-nct01346865-2015-11-16`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01346865, source copy `cardio:ctgov-nct01346865-2015-11-16`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01346865, source copy `cardio:ctgov-nct01346865-2015-11-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01346865-2015-11-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
- Condition: Coronary Artery Disease
- Intervention (Drug): Cilostazol
- Intervention (Drug): Placebo
- Lead sponsor: Seung-Jung Park
- Lead sponsor class: OTHER
- Collaborator: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Seung-Jung Park (`cardio:org-seung-jung-park`)
- Registry lists this organization as a collaborator: Otsuka Pharmaceutical Development & Commercialization, Inc. (`cardio:org-otsuka-pharmaceutical-development-commercialization-inc`)

## Provenance

Content hash: 63dd3ff8c9fcd6fb86af72a07e8bcad7c9696272aec34c2f49f8e05e4d74be62
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
